房颤与缺血性心脏病:超越中风预防

Q4 Medicine
Eduardo Alegría Ezquerra , Rosa Agra Bermejo , Luis Javier Alonso Perez , Miguel Ángel Fernández Fernández , Jose Manuel Vázquez Rodríguez , Óscar Díaz Castro , Marisol Bravo Amaro , Ramón Ríos Vázquez , Julio Martí-Almor
{"title":"房颤与缺血性心脏病:超越中风预防","authors":"Eduardo Alegría Ezquerra ,&nbsp;Rosa Agra Bermejo ,&nbsp;Luis Javier Alonso Perez ,&nbsp;Miguel Ángel Fernández Fernández ,&nbsp;Jose Manuel Vázquez Rodríguez ,&nbsp;Óscar Díaz Castro ,&nbsp;Marisol Bravo Amaro ,&nbsp;Ramón Ríos Vázquez ,&nbsp;Julio Martí-Almor","doi":"10.1016/S1131-3587(20)30012-1","DOIUrl":null,"url":null,"abstract":"<div><p>The main aim of management in patients with atrial fibrillation is to reduce the risk of stroke using appropriate antithrombotic treatment. However, despite adequate anticoagulation, there remains a substantial residual risk of ischemic events, particularly myocardial infarction and cardiovascular death. A more general approach is needed. Consequently, in patients with atrial fibrillation, anticoagulation treatment should seek to achieve the twin targets of reducing the risk of both stroke and ischemic events. Studies have demonstrated that vitamin K antagonists reduce the risk of stroke and ischemic events only when anticoagulation control is optimal, a situation that occurs in only a small number of patients. Direct oral anticoagulants are generally more effective and safer than vitamin K antagonists. However, not all direct oral anticoagulants appear to offer the same protection against ischemic events. It has been shown that rivaroxaban significantly reduces the risk of myocardial infarction (by 18%). In fact, studies demonstrate that rivaroxaban provides comprehensive vascular protection across a range of clinical scenarios, not only in patients with atrial fibrillation, but also in those with atherosclerotic vascular disease.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Fibrilación auricular y cardiopatía isquémica: más allá de la prevención del ictus\",\"authors\":\"Eduardo Alegría Ezquerra ,&nbsp;Rosa Agra Bermejo ,&nbsp;Luis Javier Alonso Perez ,&nbsp;Miguel Ángel Fernández Fernández ,&nbsp;Jose Manuel Vázquez Rodríguez ,&nbsp;Óscar Díaz Castro ,&nbsp;Marisol Bravo Amaro ,&nbsp;Ramón Ríos Vázquez ,&nbsp;Julio Martí-Almor\",\"doi\":\"10.1016/S1131-3587(20)30012-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The main aim of management in patients with atrial fibrillation is to reduce the risk of stroke using appropriate antithrombotic treatment. However, despite adequate anticoagulation, there remains a substantial residual risk of ischemic events, particularly myocardial infarction and cardiovascular death. A more general approach is needed. Consequently, in patients with atrial fibrillation, anticoagulation treatment should seek to achieve the twin targets of reducing the risk of both stroke and ischemic events. Studies have demonstrated that vitamin K antagonists reduce the risk of stroke and ischemic events only when anticoagulation control is optimal, a situation that occurs in only a small number of patients. Direct oral anticoagulants are generally more effective and safer than vitamin K antagonists. However, not all direct oral anticoagulants appear to offer the same protection against ischemic events. It has been shown that rivaroxaban significantly reduces the risk of myocardial infarction (by 18%). In fact, studies demonstrate that rivaroxaban provides comprehensive vascular protection across a range of clinical scenarios, not only in patients with atrial fibrillation, but also in those with atherosclerotic vascular disease.</p></div>\",\"PeriodicalId\":34926,\"journal\":{\"name\":\"Revista Espanola de Cardiologia Suplementos\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Espanola de Cardiologia Suplementos\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1131358720300121\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola de Cardiologia Suplementos","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1131358720300121","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

管理心房颤动患者的主要目的是通过适当的抗血栓治疗来降低卒中的风险。然而,尽管有充分的抗凝,仍然存在大量的缺血性事件残留风险,特别是心肌梗死和心血管死亡。需要一种更普遍的方法。因此,在房颤患者中,抗凝治疗应寻求实现降低卒中和缺血性事件风险的双重目标。研究表明,维生素K拮抗剂只有在抗凝控制最佳的情况下才能降低中风和缺血性事件的风险,这种情况只发生在少数患者中。直接口服抗凝剂通常比维生素K拮抗剂更有效、更安全。然而,并不是所有的直接口服抗凝剂都能对缺血事件提供相同的保护。研究表明,利伐沙班可显著降低心肌梗死的风险(降低18%)。事实上,研究表明,利伐沙班在一系列临床情况下提供全面的血管保护,不仅适用于心房颤动患者,也适用于动脉粥样硬化性血管疾病患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Fibrilación auricular y cardiopatía isquémica: más allá de la prevención del ictus

The main aim of management in patients with atrial fibrillation is to reduce the risk of stroke using appropriate antithrombotic treatment. However, despite adequate anticoagulation, there remains a substantial residual risk of ischemic events, particularly myocardial infarction and cardiovascular death. A more general approach is needed. Consequently, in patients with atrial fibrillation, anticoagulation treatment should seek to achieve the twin targets of reducing the risk of both stroke and ischemic events. Studies have demonstrated that vitamin K antagonists reduce the risk of stroke and ischemic events only when anticoagulation control is optimal, a situation that occurs in only a small number of patients. Direct oral anticoagulants are generally more effective and safer than vitamin K antagonists. However, not all direct oral anticoagulants appear to offer the same protection against ischemic events. It has been shown that rivaroxaban significantly reduces the risk of myocardial infarction (by 18%). In fact, studies demonstrate that rivaroxaban provides comprehensive vascular protection across a range of clinical scenarios, not only in patients with atrial fibrillation, but also in those with atherosclerotic vascular disease.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Revista Espanola de Cardiologia Suplementos
Revista Espanola de Cardiologia Suplementos Medicine-Cardiology and Cardiovascular Medicine
CiteScore
1.20
自引率
0.00%
发文量
1
期刊介绍: Revista Española de Cardiología, is an international scientific journal dealing with cardiovascular medicine. Revista Española de Cardiología, the official publication of the Spanish Society of Cardiology, publishes research articles related to cardiovascular diseases. Articles are published in Spanish for the paper edition and in both Spanish and English in the electronic edition, which is available on the Internet. Regular sections include original articles reporting clinical or basic research, brief reports, review articles, editorials and letters to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信